SAN RAFAEL, Calif.–(BUSINESS WIRE)– #GDBYouthPrograms–Guide Dogs for the Blind (GDB) has a new program coming out of the starting blocks in April, when it launches Ready, Set, FORWARD, a series of virtual workshops about the guide dog lifestyle aime…
Author: Business Wire
Price Vision Group Participating in Clinical Study of Investigational Growth Factor Treatment for Eye Disorder, Fuchs Endothelial Corneal Dystrophy
INDIANAPOLIS–(BUSINESS WIRE)–Price Vision Group participating in clinical trial of investigational growth factor treatment for eye disorder, Fuchs Corneal Endothelial Dystrophy
Aldeyra Therapeutics to Present at the OIS Dry Eye Innovation Showcase on March 11, 2021
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and Chief Executive Officer Todd C. Brady, M.D., Ph.D. will discuss the potential of reproxalap as a novel, rapid-onset first-line tre…
LENSAR Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for …
Samsara Vision and Medevise Consulting Announce European Partnership
FAR HILLS, N.J.–(BUSINESS WIRE)–Samsara Vision will partner with Medevise Consulting to build a dedicated commercial organization to support Samsara Vision’s Tsert SI IMT.
Mydriasert: An Ophthalmic Insert Containing 0.28mg Tropicamide and 5.4mg Phenylephrine Hydrochloride – Global Drug Insight and Market Forecast to 2030 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Mydriasert – Drug Insight and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering. The product details covers mechanism of action, dosage and administration, route of synthesis, and pharmacol…
National Vision Names 2020-2021 Grant Program Winners, Awarding $7,000 Total to Optometry Students
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE), one of the nation’s largest optical retailers providing quality, affordable eye care and eyewear, has awarded $7,000 in grants to three third- and fourth-year optometry student…
New ZEISS AntiFOG Wipes Come to the Aid of Eyeglass Wearers Frustrated by Fogged Lenses Caused by Face Masks
SAN DIEGO–(BUSINESS WIRE)–Carl Zeiss Vision, Inc. announces availability of ZEISS AntiFOG Wipes to keep glasses fog free even for mask wearers.
Visus Therapeutics Announces $36 Million Series A Financing to Advance Development of Novel Presbyopia-Correcting Eye Drop
SEATTLE–(BUSINESS WIRE)–Visus Therapeutics announces a $36 million Series A financing round to advance the development of BRIMOCHOL, its novel presbyopia-correcting eye drop
Teva Announces Launch of First Generic Version of AZOPT® (brinzolamide ophthalmic suspension) 1%, used to treat high pressure inside the eye, in the United States
TEL AVIV & PARSIPPANY, N.J.–(BUSINESS WIRE)–Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd.(NYSE and TASE: TEVA), today announced its launch of the first available generic version of AZOPT® (brinzolamide ophtha…
Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients
DAEJEON, South Korea–(BUSINESS WIRE)– #196170KQ–Alteogen completed a Phase 1 clinical trial of Eylea® Biosimilar (ALT-L9) in wet AMD patients at 4 major hospitals in Korea.
Glaukos to Support World Glaucoma Week with Patient Education Campaign and Free Screening Initiatives
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced two n…
NovaBay Pharmaceuticals to Participate in Virtual 33rd Annual Roth Conference
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay Pharmaceuticals (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova® for the eye care market and CelleRx® Clinical Reset™ for the beauty market, announces that management will …
Razer Anzu Smart Glasses Combine Multi-Lens Eyecare and Open-Ear Audio to Connect in Style
IRVINE, Calif.–(BUSINESS WIRE)– #audio–Razer Anzu Smart Glasses are Razer’s first smart eyewear and will be available in Best Buy and Razer.com starting March 4th, 2021.
Standigm Secures $44.5 M in Pre-IPO Funding Round
SEOUL, South Korea–(BUSINESS WIRE)– #AI–Standigm, a leading AI-based drug discovery company, raised $44.5 M in a Pre-IPO round to go public on the Korea Exchange later in 2021.
National Vision Holdings, Inc. Announces Participation in the Bank of America Consumer and Retail Technology Conference
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) today announced the Company is scheduled to present at the Bank of America Consumer and Retail Technology Conference 2021 on Tuesday, March 9, 2021 at 2:30 p.m. Eastern Time. A …
Second Sight Medical Products, Inc. Receives FDA Approval for the Argus 2s Retinal Prosthesis System
LOS ANGELES–(BUSINESS WIRE)–Second Sight Medical Products (NASDAQ:EYES) a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced U.S. Foo…
2021 Global Competitor Strategies in Eyewear: Strongly Positioned Brands And An Established Digital Strategy Are Key – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Competitor Strategies in Eyewear” report has been added to ResearchAndMarkets.com’s offering. 2020 was a year that shook up the eyewear industry. While most key players will suffer in 2021, the severity of the impact of th…
Ocular Therapeutix™ Announces FDA Acceptance of Supplemental New Drug Application for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today …
LENSAR to Hold Fourth Quarter and Full Year 2020 Financial Results and Business Update Conference Call on Wednesday, March 10, 2021
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s fou…